Fly News Breaks for March 7, 2019
Mar 7, 2019 | 07:23 EDT
Wedbush analyst Robert Driscoll lowered his price target for Idera Pharmaceuticals to $7 from $16 after he tweaked his market assumptions for tilosotolimod in refractory melanoma to be more conservative as the landscape evolves. The analyst continues to see tilsotolimod as a differentiated I-O asset that is being developed in a rational I-O clinical strategy, and reiterates an Outperform rating on the shares.
News For IDRA From the Last 2 Days
There are no results for your query IDRA